"In this regard, it is interesting that, in
addition to the known deregulation in leukemias and lymphomas, genome-wide
expression studies have shown that Bcl-3 is overexpressed in breast cancer,
glioblastoma tumors,
ovarian cancer and, intriguingly, teratomas and embryonal>
carcinomas (additional file 2). Although not validated, these results support the
potential importance of this oncogene in a variety of tumors."
Role of Bcl-3 in solid tumors
Vilma Maldonado and Jorge Melendez-Zajgla
Molecular Cancer 2011,
10:152
doi:10.1186/1476-4598-10-152
Published: 23 December 2011
Abstract (provisional)
Bcl-3 is an established
oncogene in hematologic malignancies, such as B-cell chronic
lymphocytic leukemias. Nevertheless, recent research has shown that it also participates
in progression of diverse
solid tumors. The present review summarizes the current
knowledge of Bcl3 role in solid tumors progression, including some new insights in
its possible molecular mechanisms of action
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
